Short description
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.
Description
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.
Last funding
Uh Ohhhh
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Ann Arbor, Michigan, United States, North America
Founded on
January 1, 1998
Exited on
July 5, 2013
Went public on
July 5, 2013
Stock symbol
ESPR
Non-profit?
No
Acquired?
No
Employees count
101-250
Revenue range
$7890 - 12340
Sign in for full access
Investors
Absolutely Noaccess, Noaccess, Blurry Noaccess, Noaccess, Noaccess, Noaccessforu, Cannot Access
Sign in for full access
Founders
Roger S. Newton